• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

    22.69 -1.09 (-4.58%)
    Streaming Delayed Price Updated: 1:28 PM EDT, May 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 141,299
    Open 23.80
    Bid (Size) 22.67 (200)
    Ask (Size) 22.76 (200)
    Prev. Close 23.78
    Today's Range 22.60 - 23.80
    52wk Range 7.800 - 24.25
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 ↗
    This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
    From Bicara Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +38.5%
    +38.5%
    1 Month
    +8.8%
    +8.8%
    3 Month
    +38.6%
    +38.6%
    6 Month
    +60.5%
    +60.5%
    1 Year
    +79.1%
    +79.1%

    More News

    Read More
    News headline image
    Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    News headline image
    Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Proposed Public Offering of Common Stock
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics to Participate in Upcoming Investor Conferences
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
    Via Investor Brand Network
    News headline image
    Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
    From BioMedWire
    Via GlobeNewswire
    Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
    Via Investor Brand Network
    News headline image
    Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
    Via FinancialNewsMedia
    News headline image
    These stocks that are showing activity before the opening bell on Monday. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Bicara Therapeutics Inc. - Common Stock publicly traded?
    Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
    Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
    The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
    What is the current price of Bicara Therapeutics Inc. - Common Stock?
    The current price of Bicara Therapeutics Inc. - Common Stock is 22.69
    When was Bicara Therapeutics Inc. - Common Stock last traded?
    The last trade of Bicara Therapeutics Inc. - Common Stock was at 05/07/26 01:28 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.